List of Excipients in Branded Drug TERLIVAZ

TERLIVAZ Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

TERLIVAZ is a lyophilized, preservative-free injectable formulation of terlipressin acetate for adults with hepatorenal syndrome involving rapid reduction in kidney function. Its principal commercial opportunity is not a new active ingredient but improved administration: ready-to-use liquid presentations, safer dilution systems, reduced preparation waste, and formulations that support hospital protocols and international distribution. The core barriers are peptide stability, low-volume dosing, oxygen and moisture sensitivity, container-closure performance, and the need to preserve compatibility with intravenous infusion systems.

What is TERLIVAZ and how is it administered?

TERLIVAZ contains terlipressin acetate and is supplied as a single-dose lyophilized powder in a vial. The product is reconstituted before intravenous administration with 0.9% sodium chloride injection. The approved indication is treatment of adults with hepatorenal syndrome with rapid reduction in kidney function, historically described as hepatorenal syndrome type 1.[1]

Attribute	TERLIVAZ profile
Active ingredient	Terlipressin acetate
Therapeutic class	Vasopressin analog
FDA application	NDA 217801
FDA approval	September 14, 2022
Dosage form	Lyophilized powder for injection
Route	Intravenous
Initial U.S. indication	Hepatorenal syndrome with rapid reduction in kidney function
Dosing environment	Hospital or closely supervised clinical setting
Manufacturer in U.S. labeling	Mallinckrodt Hospital Products IP Limited
Primary commercial users	Hospitals, intensive-care units, hepatology and transplant centers

Terlipressin is converted to lysine vasopressin and produces vasoconstriction, particularly in the splanchnic circulation. The product has meaningful safety-management requirements, including risks of respiratory failure, ischemic events, hypertension, bradycardia, and hyponatremia.[1]

What excipients are used in TERLIVAZ?

The TERLIVAZ presentation uses a relatively simple excipient strategy centered on lyophilization and reconstitution. FDA labeling identifies sodium chloride in the product and directs reconstitution with 0.9% sodium chloride injection.[1] The manufacturing process may also use pH-adjusting agents and processing materials that are not necessarily present as independently declared formulation excipients in the final label.

The formulation strategy has four commercial characteristics:

1. It avoids preservatives in a product intended for single-dose intravenous use.
2. It separates the active peptide from the aqueous environment during storage.
3. It relies on hospital dilution immediately before administration.
4. It creates a preparation step that can be improved through packaging and delivery innovation.

Why lyophilization is commercially relevant

Terlipressin is a peptide. Peptide products can experience hydrolysis, oxidation, aggregation, adsorption to surfaces, and potency loss in aqueous formulations. Lyophilization reduces the amount of water available for degradation during shelf life and can improve transport stability.

A successful lyophilized formulation must balance:

• Cake structure and reconstitution speed
• Residual moisture
• Peptide aggregation
• pH during reconstitution
• Osmolality
• Vial adsorption
• Extractables and leachables
• Compatibility with infusion bags and tubing

The current presentation transfers part of the preparation burden to hospital pharmacy or nursing staff. That burden creates opportunities for competitors and licensors with expertise in sterile fill-finish, peptide stabilization, and ready-to-administer packaging.

What formulation patents protect TERLIVAZ?

Publicly available FDA labeling confirms the dosage form and administration method but does not, by itself, establish the complete patent estate. The current Orange Book and relevant U.S. patent records must be reviewed for the live listed patents associated with NDA 217801.[2]

The commercially important patent categories are likely to include:

Patent category	Potentially protected subject matter	Commercial relevance
Composition	Terlipressin acetate or defined salt forms	May protect the active pharmaceutical ingredient or a specific chemical form
Lyophilized formulation	Terlipressin with stabilizers, tonicity agents, or pH modifiers	Could delay a directly substitutable injectable
Reconstitution	Defined diluent, concentration, or reconstitution conditions	May affect hospital-use alternatives
Method of treatment	Terlipressin use in hepatorenal syndrome	Relevant to labeled or carved-out indications
Dosing regimen	Bolus, infusion, dose escalation, or treatment duration	May affect generic labeling and method-of-use litigation
Container closure	Vial, stopper, overfill, or storage configuration	Usually a secondary barrier unless tied to formulation performance
Manufacturing	Lyophilization cycle, purification, or impurity control	Can create process barriers without blocking all formulations

Terlipressin itself is an established molecule with prior non-U.S. use. The strongest U.S. protection is therefore more likely to reside in regulatory exclusivity, formulation details, manufacturing controls, clinical-use claims, and product-specific patent listings than in broad basic composition claims.

When does TERLIVAZ lose exclusivity?

FDA approval occurred in 2022. The product benefits from the statutory exclusivity applicable to a new drug approval, but the exact exclusivity end date depends on the approval classification and FDA’s Orange Book listing.

For a 505(b)(2) product, the standard new-drug exclusivity period is commonly five years, subject to the applicable statutory framework and any patent-related extension. The product may also receive pediatric exclusivity if FDA grants it, which can add six months to applicable exclusivity and patent terms.[3]

Exclusivity issue	TERLIVAZ implication
FDA approval	September 2022
New-drug exclusivity	Must be confirmed in FDA regulatory records
Patent term	Depends on listed patents, PTA, PTE, and litigation
Pediatric exclusivity	No assumption should be made without an FDA grant
Generic pathway	Potential ANDA or 505(b)(2), depending on sameness and formulation
Biosimilar pathway	Not applicable because TERLIVAZ is a synthetic peptide drug rather than a biologic reference product

A generic competitor would not necessarily need to copy every excipient. It would generally need to demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA’s applicable requirements for the selected pathway. A materially different formulation could require a 505(b)(2) application.

Can generic companies file Paragraph IV challenges against TERLIVAZ?

Yes. If TERLIVAZ has patents listed in the Orange Book, an ANDA applicant could file a Paragraph IV certification against one or more listed patents. The applicant would need to establish that the patent is invalid, unenforceable, or not infringed, or it could wait until patent expiry.

Potential Paragraph IV targets include:

• Lyophilized terlipressin formulations
• Salt or purity specifications
• Reconstitution conditions
• Dosing schedules
• Methods of treating hepatorenal syndrome
• Manufacturing or storage limitations

The practical attractiveness of a Paragraph IV challenge depends on the value of the market, the number of listed patents, the breadth of the claims, the availability of non-infringing formulations, and the cost of clinical and analytical development.

For a hospital injectable, litigation economics differ from those for a high-volume oral drug. A challenger may accept a narrower commercial opportunity if it can launch a reliable product with lower manufacturing cost. The reference company may have less incentive to litigate weak formulation claims if the expected market is concentrated in a limited number of hospitals.

What commercial opportunities exist in TERLIVAZ excipients?

The highest-value opportunities involve reducing preparation risk and improving supply-chain efficiency rather than adding complex excipients.

Ready-to-use liquid formulation

A stable liquid terlipressin product could eliminate reconstitution. The commercial advantages include:

• Lower pharmacy labor
• Fewer preparation errors
• Faster administration
• Reduced vial and diluent waste
• Easier use in emergency and intensive-care settings
• Better standardization across hospitals

The principal technical challenge is maintaining peptide stability in water over the intended shelf life. A liquid product may require optimized pH, antioxidant control, low-oxygen filling, nitrogen overlay, specialized container closure, or a redesigned salt and buffer system.

Dual-chamber vial or prefilled syringe

A dual-chamber system could keep terlipressin dry while integrating the diluent into one device. It would preserve some stability advantages of lyophilization while reducing manipulation.

A prefilled syringe could support dose standardization, but the product would require careful assessment of peptide adsorption, silicone oil, tungsten residues, needle compatibility, and extractables. The small dose volume makes device accuracy particularly important.

Improved lyophilized formulation

A new lyophilized composition could use a stabilizer or bulking agent to improve cake appearance, reconstitution time, or long-term potency. Candidate excipient classes may include:

• Polyols such as mannitol or sorbitol
• Sugars such as sucrose or trehalose
• Amino acids such as glycine
• Low-concentration buffers
• Surfactants to reduce interfacial adsorption
• Antioxidant systems where chemically justified

Any excipient change must be evaluated for peptide aggregation, subvisible particles, reconstitution time, pH drift, and compatibility with intravenous administration. A formulation that improves stability but creates particulates or hemolysis risk would have limited value.

Co-packaged diluent

A co-packaged vial with the required sodium chloride diluent is a lower-risk commercial improvement. It can reduce pharmacy inventory complexity and eliminate selection of the wrong diluent or volume.

The main IP opportunity is likely packaging and presentation protection rather than a broad excipient patent. Regulatory value may exceed patent value if the product is easier for hospitals to purchase and administer.

How strong is the TERLIVAZ patent estate?

The patent estate should be assessed as moderate rather than assumed to be broad. Terlipressin is an established peptide, and broad molecule-level claims may face prior-art limitations. Protection can still be commercially meaningful if it covers the approved lyophilized formulation, a narrow but necessary reconstitution condition, or a clinically important dosing regimen.

Factors supporting stronger protection

• A narrow formulation claim tied to unexpected stability
• Specific impurity or aggregation limits
• A clinically validated dosing regimen
• Patents covering a required presentation or device
• Regulatory exclusivity that expires after patent filing opportunities have matured

Factors weakening protection

• Easy substitution of standard injectable excipients
• Prior art covering terlipressin salts and lyophilization
• Ability to develop a non-infringing liquid or powder formulation
• Limited sales volume relative to litigation costs
• Method-of-use claims that can be avoided through labeling

The strongest competitive barrier may be a combination of know-how, sterile manufacturing capability, hospital contracting, and regulatory execution rather than a single patent claim.

What regulatory status and Orange Book issues matter?

TERLIVAZ is FDA-approved under NDA 217801.[1] The product is not a biologic, so biosimilar approval under the Public Health Service Act is not the expected competitive pathway. Competition is more likely to arise through an ANDA or 505(b)(2) application.

Orange Book diligence should examine:

• Listed patents and their expiration dates
• Patent use codes
• Whether each claim covers the approved indication or dosage form
• Pediatric exclusivity
• Patent-term adjustment or extension
• Pending delisting disputes
• Any approved supplements affecting formulation or presentation

A formulation competitor should also review FDA’s product-specific guidance, where available, and determine whether the agency expects comparative physicochemical testing, pharmacokinetic studies, clinical endpoint data, or a combination.

Which companies are positioned to challenge TERLIVAZ?

Potential challengers fall into four groups:

1. Generic injectable manufacturers with sterile lyophilization capacity.
2. Specialty pharmaceutical companies focused on hospital products.
3. Contract development and manufacturing organizations with peptide fill-finish capability.
4. Device companies partnering with a drug sponsor to create a dual-chamber or ready-to-use presentation.

The most credible challenger is unlikely to be a conventional oral-generic company without sterile injectable infrastructure. Terlipressin requires controlled peptide manufacturing, aseptic processing, analytical characterization, and pharmacovigilance for a drug with serious cardiovascular and respiratory risks.

What licensing opportunities exist?

Licensing opportunities are strongest in four areas:

Opportunity	Likely partner	Value proposition
Stable liquid terlipressin	Peptide formulation company	Removes reconstitution and improves hospital workflow
Dual-chamber presentation	Drug-device developer	Combines lyophilized stability with simplified administration
Regional manufacturing	Injectable manufacturer	Expands geographic access and lowers supply cost
Hospital-use package	Specialty pharma or distributor	Bundles diluent, administration supplies, and dosing guidance

A licensee should seek rights that cover formulation, device, manufacturing process, and geographic markets together. A formulation-only license may have limited value if the sponsor lacks a protected route to market or a reliable sterile manufacturing partner.

What is the revenue exposure to generic entry?

TERLIVAZ is a hospital product used for a serious but relatively narrow indication. Revenue exposure depends on diagnosis rates, treatment adoption, hospital protocols, reimbursement, and the ability of clinicians to manage adverse events.

A generic launch could produce:

• Rapid price erosion in tenders and hospital contracts
• Lower net pricing without immediate volume expansion
• Substitution pressure if the generic matches the reference presentation
• Slower substitution if hospitals prioritize supply reliability and preparation safety
• Limited erosion if the reference company controls a differentiated ready-to-use product

A ready-to-use TERLIVAZ formulation could defend commercial value even after powder-form exclusivity weakens. The product would need to show lower total cost of care or lower medication-use risk, not only a different excipient profile.

What manufacturing and IP barriers affect competitors?

The principal barriers are technical and operational:

• Peptide purity and impurity control
• Reproducible lyophilization
• Low residual moisture
• Sterile fill-finish
• Container-closure integrity
• Stability-indicating analytical methods
• Control of aggregation and subvisible particles
• Reliable supply of terlipressin acetate
• Hospital-scale packaging and distribution

A competitor can avoid a formulation patent but still face lengthy development if it must establish a stable product and demonstrate pharmaceutical equivalence. Manufacturing know-how may therefore extend effective protection beyond the formal patent term.

Key Takeaways

• TERLIVAZ is a lyophilized terlipressin acetate injectable approved by FDA in 2022.
• Its current excipient strategy relies on a dry powder presentation, sodium chloride, and hospital reconstitution.
• The clearest commercial opportunity is a stable ready-to-use liquid, dual-chamber vial, or prefilled device.
• A co-packaged diluent offers a lower-risk improvement with potential workflow and procurement benefits.
• Generic competition is more likely through an ANDA or 505(b)(2) application than through a biosimilar pathway.
• Patent strength will depend on formulation, dosing, method-of-use, manufacturing, and device claims rather than only the terlipressin molecule.
• Hospital adoption, sterile manufacturing, analytical capability, and supply reliability may be as important as patent scope.
• Patent and Orange Book conclusions require current review of FDA’s listed patents and exclusivity records.

FAQs

Is TERLIVAZ a biologic that can face biosimilar competition?

No. TERLIVAZ contains terlipressin acetate, a synthetic peptide drug. Competition is expected through generic or 505(b)(2) pathways rather than the biosimilar pathway.

Can a competitor use different excipients from TERLIVAZ?

Potentially. A competitor may use a different excipient system if it meets FDA requirements for the selected regulatory pathway and does not infringe valid formulation claims.

Would a liquid terlipressin product be automatically substitutable with TERLIVAZ?

No. Substitutability depends on FDA approval, dosage-form equivalence, labeling, pharmacy law, and the product-specific regulatory pathway.

What is the most valuable excipient innovation for terlipressin?

A stability-proven liquid or dual-chamber presentation that removes reconstitution while maintaining peptide integrity has the highest potential commercial value.

Does a Paragraph IV challenge guarantee an early generic launch?

No. A Paragraph IV filing can trigger patent litigation and a potential 30-month stay of approval under applicable law. Launch timing depends on litigation outcomes, settlements, exclusivity, and FDA approval status.

References

1. U.S. Food and Drug Administration. (2022). TERLIVAZ (terlipressin acetate) for injection: Prescribing information. Mallinckrodt Hospital Products IP Limited.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Regulatory exclusivity and patent information for approved drug products. https://www.fda.gov/drugs/development-resources/patent-and-exclusivity-information

4. U.S. Food and Drug Administration. (2022). FDA approves treatment to improve kidney function in adults with hepatorenal syndrome. https://www.fda.gov/news-events/press-announcements

5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary: General chapters for injectable drug products and pharmaceutical compounding. United States Pharmacopeial Convention.